« Return to News | CROs/Service Providers

Private Equity Group Acquires Radiant Research to Grow the SMO Globally

Monday, June 11, 2007 10:20 AM

Bellevue, Wash.-based Radiant Research, the largest owned-model site management organization (SMO) with 26 sites, has completed a sale of the business to an ownership group led by ICICI Venture, a private equity company with $2 billion under management. Company officials said June 8th that Radiant will continue to provide development, study conduct and centralized patient recruitment services.

Radiant Research has undergone many changes lately. In May 2006, Radiant Research sold its eight phase I units to Covance for $65 million. Those phase I units generated $25 million in annual revenue. Founder and former chief executive officer Mike Lester left the company in August 2006.

“After the sale of our phase I business unit, we refocused our attention to our core business units, which consist of Radiant Research for phase II-IV study conduct services, Radiant Development for CRO services and Radiant Recruitment, which offers centralized recruitment services for the biopharmaceutical industry,” said Spaniac.

Spaniac and the management team at Radiant will remain at the company. Radiant has 400 employees and an estimated $70 million in annual revenues.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.